Latest Research And Development News

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

Calix Limited reported a solid 21% revenue increase for the half-year ending December 2025, but losses ballooned by 250%, raising questions about the path to profitability.

Nanosonics Limited reported a 9% revenue increase in the first half of FY26, driven by a growing installed base and recurring sales, while advancing the commercial rollout of its new CORIS endoscope reprocessing system.

PYC Therapeutics reported a narrowed half-year loss of $22.8 million while progressing four RNA drug candidates through clinical stages. The company announced a major $653 million capital raising to extend its cash runway to 2030 and support ongoing development.

Lumos Diagnostics has hit a key enrollment milestone in its BARDA-funded paediatric study for FebriDx®, unlocking a US$720,000 payment and edging closer to FDA expansion.

VEEM Limited reports half-year revenue close to guidance with improved cash flow, offset by a significant $24.8 million non-cash impairment tied to its gyro product upgrade. The transition to the new Mark III gyro design has temporarily stalled sales as customers await delivery.

Praemium Limited reported a robust half-year performance with a 69.5% jump in net profit and a 9.6% rise in funds under administration, completing the OneVue platform transition and acquiring AI specialist Technotia Laboratories.

Nuix Limited has reported robust half-year results for 1H26, highlighted by a 148% increase in Nuix Neo Annualised Contract Value and a significant boost in profitability and cash flow.

Elixir Energy has locked in a $10 million debt facility secured against its FY26 R&D tax refund to fund the Lorelle-3 appraisal well activities in Queensland’s Taroom Trough. This financial move aims to bolster working capital during a busy operational period.

Legend Mining has received an $811,458 cash refund from the Australian Taxation Office for its FY2025 R&D claim, lifting its cash position to nearly $11 million.

WA Kaolin reported $2.7 million in sales for the December quarter, secured a $1.5 million working capital loan, and restructured $20.4 million of debt, while focusing on plant improvements and cost reductions to address negative margins.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.